sunpharma news

Sun Pharmaceutical Industries Ltd SUN.NS * Says validation of regulatory filing of tildrakizumab with the european medicines agency (EMA) by Almirall. * Tildrakizumab is an investigational IL-23P19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. * Filing includes efficacy, safety data from pivotal phase III clinical trials that included over 1,800 patients Source text - Further company coverage: SUN.NS